Can't see how the market sees it as 'does not work'. The evidence is there. Remember when assessing utility of a novel treatment, the criteria is safety, efficacy and cost effectiveness. The trials show that MSB's product is safe and effective. Now the presentation provides a list of the alternative treatments for AGVHD and their pricing and based on pricing elsewhere, our's will be competitive. That's three boxes ticked for me.
Everyone is a little bit different, but I personally (as a LTH) can't see this being the point to sell out. The product is there, the evidence is there, the manufacturing process is there, and the cash is there. Even it is a gamble, I see the odds in my favour at this point and am happy to go with fate.
Add to My Watchlist
What is My Watchlist?
